Share this article on:

Harnessing the Power of Genetic Engineering for Patients With Mitochondrial Eye Diseases

Yu-Wai-Man, Patrick PhD, FRCPath, FRCOphth

Journal of Neuro-Ophthalmology: March 2017 - Volume 37 - Issue 1 - p 56–64
doi: 10.1097/WNO.0000000000000476
Bench to Bedside

Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne, United Kingdom; Newcastle Eye Centre, Royal Victoria Infirmary, Newcastle upon Tyne, United Kingdom; and NIHR Biomedical Research Centre, Moorfields Eye Hospital and UCL Institute of Ophthalmology, London, United Kingdom.

Address correspondence to Patrick Yu-Wai-Man, PhD, FRCPath, FRCOphth, Wellcome Trust Centre for Mitochondrial Research, Institute of Genetic Medicine, Newcastle University, Newcastle upon Tyne NE1 3BZ, United Kingdom; E-mail: Patrick.Yu-Wai-Man@ncl.ac.uk

P. Yu-Wai-Man is supported by a Clinician Scientist Fellowship Award (G1002570) from the Medical Research Council (MRC, United Kingdom). P. Yu-Wai-Man also receives funding from Fight for Sight (United Kingdom), the UK National Institute of Health Research (NIHR) as part of the Rare Diseases Translational Research Collaboration, and the NIHR Biomedical Research Centre based at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology.

P. Yu-Wai-Man holds a consultancy agreement with GenSight Biologics (Paris, France).

The views expressed are those of the author and not necessarily those of the NHS, the NIHR or the Department of Health.

© 2017 by North American Neuro-Ophthalmology Society